Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. This will ultimately save time and money in drug development.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

NOVEMBER 3, 2022

Small molecule and biologics targeted screening for GPCRs, kinases, ion channels, interleukins, checkpoints, novel targets and a few case studies. Integrated drug discovery advantages to be able to run a successful and fully integrated drug development program.

Computational Chemistry 130

Computational Chemistry Small Molecule Drug Development Drugs 130

Drug Discovery World

FEBRUARY 5, 2024

Opening keynote Following a change to the schedule, Juliet Williams of Kymera Therapeutics launched the event with a popular keynote talk ‘Solving Big Problems with Small Molecule Degraders’.

Small Molecule 163

Small Molecule Assay Development Production Science 163

Drug Discovery World

NOVEMBER 3, 2022

Small molecule and biologics targeted screening for GPCRs, kinases, ion channels, interleukins, checkpoints, novel targets and a few case studies. Integrated drug discovery advantages to be able to run a successful and fully integrated drug development program.

Computational Chemistry 130

Computational Chemistry Small Molecule Drug Development Drugs 130

Drug Discovery World

MARCH 12, 2024

Lastly, for treatment of substance use disorders, few pipeline drugs are currently undergoing clinical trials, yet those in trial only address the withdrawal symptoms but not the underlying reward circuitry and the cravings. RA: What advantages does a plant-based approach bring to drug development?

Small Molecule 148

Small Molecule Synthetic Chemistry Production Molecular Biology 148

Drug Discovery World

OCTOBER 20, 2022

This is the latest episode of the free DDW podcast, “What does the changing drug discovery and development landscape mean for the future?”. In the first article, he talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.

Small Molecule 130

Small Molecule Pharmaceuticals Drugs Science 130

Drug Discovery World

OCTOBER 20, 2022

This is the latest episode of the free DDW podcast, “What does the changing drug discovery and development landscape mean for the future?”. In the first article, he talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.

Small Molecule 130

Small Molecule Drugs Pharmaceuticals Science 130

DrugBank

MAY 15, 2024

Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. One approach is to look beyond the traditional drug molecule.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

DrugBank

JULY 24, 2024

Breaking New Ground with PROTACs One of the standout innovations in this space is the development of proteolysis-targeting chimeras, or PROTACs. These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

FEBRUARY 22, 2023

More than 20% of new drugs are now coming from small innovative organisations and this percentage is increasing exponentially as these small organisations adopt this new technology.

Small Molecule 130

Small Molecule Drug Development Drugs Packaging 130

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds.

Drug Development 98

Drug Development Drugs Pharmaceutical Companies Clinical Development 98

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. In cancer, PGE2 acts in the tumour microenvironment to trigger cancer cells to evade the immune system.

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

FEBRUARY 13, 2024

The attention on this tool brought further waves of interest into how AI could be deployed across the pharmaceutical and drug discovery sectors. However, that’s not to say the future of drug discovery isn’t exciting, or that AI won’t play a part in it, just that the potential of AI within pharma has yet to be reached.

Small Molecule 148

Small Molecule Drugs Therapies Pharmaceutical Companies 148

Drug Discovery World

APRIL 5, 2023

CBC members are selected in five-year cycles and chosen for their knowledge and expertise in small molecule drug discovery and high-level capabilities to advance projects from target validation to clinical candidate selection.

Small Molecule 130

Small Molecule Cell Biology Laboratories Engineering 130

Drug Discovery World

DECEMBER 21, 2023

Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

FDA Approval 148

FDA Approval Therapies Small Molecule Clinical Trials 148

Drug Discovery World

DECEMBER 26, 2023

Anagenex and Nimbus Therapeutics Anagenex and Nimbus Therapeutics have initiated a research collaboration to discover small molecule drugs for multiple challenging targets. Peter Tummino, Nimbus’ Chief Scientific Officer, said: “At Nimbus, we have prioritised important but difficult-to-drug targets across multiple therapy areas.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

SCIENMAG: Medicine & Health

MARCH 26, 2024

Credit: Redox Medicine […]

Small Molecule 78

Small Molecule International Drug Development Drugs 78

BMG Labtech

APRIL 16, 2024

In this blog, we take stock of progress, look at what’s in store for drug development, and give examples of ways microplate readers can help advance research into molecular glues. Conventional drug development has often focused on finding small molecules that fit the active site of a protein.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Drug Development Disease 40

Drug Discovery World

MARCH 2, 2023

Mari Goldsmith, Application Scientist at Torx Software and John Kratunis, Manager, Customer Success Specialists, NA at CAS will demonstrate the power of combining Torx with CAS SciFinder n to ensure the correct decisions are made quickly to deliver new drugs faster. Register for free here.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 23, 2023

Mari Goldsmith, Application Scientist at Torx Software and John Kratunis, Manager, Customer Success Specialists, NA at CAS will demonstrate the power of combining Torx with CAS SciFinder n to ensure the correct decisions are made quickly to deliver new drugs faster. Register for free here.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 16, 2023

Mari Goldsmith, Application Scientist at Torx Software and John Kratunis, Manager, Customer Success Specialists, NA at CAS will demonstrate the power of combining Torx with CAS SciFinder n to ensure the correct decisions are made quickly to deliver new drugs faster. Register for free here.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 9, 2023

Mari Goldsmith, Application Scientist at Torx Software and John Kratunis, Manager, Customer Success Specialists, NA at CAS will demonstrate the power of combining Torx with CAS SciFinder n to ensure the correct decisions are made quickly to deliver new drugs faster. Register for free here.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

FEBRUARY 6, 2023

Users can add the dedicated CAS SciFinder plugin window to their Torx design environment to search and display the results in CAS SciFinder, alongside real-time critical physico-chemical, near-neighbor, and 3D-pose information about their small molecules in Torx. Learn more about the CAS and Torx software collaboration at the upcoming webinar ‘Connected (..)

Small Molecule 130

Small Molecule Research Drugs Drug Development 130

Drug Discovery World

FEBRUARY 2, 2023

Mari Goldsmith, Application Scientist at Torx Software and John Kratunis, Manager, Customer Success Specialists, NA at CAS will demonstrate the power of combining Torx with CAS SciFinder n to ensure the correct decisions are made quickly to deliver new drugs faster. Register for free here.

Small Molecule 130

Small Molecule Drugs Research Drug Development 130

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

DrugBank

MAY 22, 2024

Molecular dynamics (MD) simulations and other computational methods are vital tools in our arsenal , helping us peek into the atomic-level interactions and movements within the protein, helping reveal potential new binding sites induced by small molecule interactions. DNA and RNA are also key players, each bringing unique challenges.

Small Molecule 67

Small Molecule RNA DNA Pharmaceutical Companies 67

Drug Discovery World

APRIL 12, 2023

Such insights are helping drug hunters to design novel drug development strategies. It is our capability to build strategic alliances that include all interested parties that will truly reshape the traditional way of developing therapeutic agents. Biography: Dr Alessandro Carugo is Director of Oncology at IRBM.

Drugs 130

Drugs Small Molecule Treatment Drug Development 130

Drug Discovery World

JANUARY 13, 2023

The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases. . Cambrian expands fibrosis pipeline .

Small Molecule 130

Small Molecule RNA Drugs Engineering 130

Drug Discovery World

FEBRUARY 27, 2023

For founders planning to launch their start-ups, specifically drug developers, there needs to be sound, foundational science with promising data that will enable you to push further down the drug discovery pipeline. Do you have any therapeutic targets in mind for your first small molecule drug candidate?

RNA 130

RNA Science Small Molecule Engineering 130

Drug Discovery World

OCTOBER 21, 2022

Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). .

Small Molecule 130

Small Molecule Virus Drugs Clinical Trials 130

Drug Target Review

JULY 13, 2023

By capitalising on condensate biology, Dewpoint seeks to tackle diseases and targets that have previously lacked sufficient understanding for effective drug discovery. Dewpoint addresses diseases that lacked comprehensive biological understanding, allowing for more meaningful and logical drug discovery efforts.

Disease 98

Disease Small Molecule Cell Biology Medical Schools 98

Broad Institute

NOVEMBER 2, 2023

Combining Broad’s expertise in cancer biology and state-of-the-art drug discovery methods with Bayer’s expertise in drug development greatly increases our power to bring transformative medicines to cancer patients.” “We “Through this alliance, Broad and Bayer have done just that.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

PPD

OCTOBER 18, 2023

As exponential growth and global expansion continue in both the biotech and pharmaceutical industries, it is critical for drug development companies to partner with good manufacturing practices (GMP) / chemistry manufacturing and controls (CMC) contract labs to conduct analyses of a range of small molecules and biologics and drive therapies forward (..)

Laboratories 52

Laboratories Assay Development Small Molecule Packaging 52

LifeSciVC

AUGUST 5, 2024

We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more. One final parallel to 2001.

Molecular Biology 90

Molecular Biology Production Small Molecule Drug Development 90

The Pharma Data

FEBRUARY 24, 2022

Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development. They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme.

Small Molecule 52

Small Molecule Cell Biology Research Drug Development 52